Ipsen Quote - IPN

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

110.20

Bid

110.00

Offer

110.60

Volume

23,107

109.90 Day's Range 110.80

99.70 52 Week Range 126.70

Market Cap

9.04B

Previous Close

110.60

Open

110.60

Last Trade

110.2

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

61,132

Shares Outstanding

82,029,421

Dividend Yield

1.09%

PE Ratio

14.03

Earnings Per Share (EPS)

7.86

Revenue

3.37B

Net Profit

644.4M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.ipsen.com

Headquarters

Boulogne-billancourt, Hauts-de-seine, Fra

Founded

Ipsen SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker IPN. The last closing price for Ipsen was 110.60 €. Over the last year, Ipsen shares have traded in a share price range of 99.70 € to 126.70 €.

Ipsen currently has 82,029,421 shares in issue. The market capitalisation of Ipsen is 9.07 € billion. Ipsen has a price to earnings ratio (PE ratio) of 14.03.

Ipsen - Novembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Ipsen - Novembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de...

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights...

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology Ipsen secures exclusive global rights to develop, manufacture and...

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with first-in-class potentialBMX-502 is a bispecific antibody...

Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules MAIT, une nouvelle classe thérapeutique en immuno-oncologie

Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules MAIT, une nouvelle classe thérapeutique en immuno-oncologie Ipsen obtient les droits mondiaux...

Bylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les patients atteints de CIFP et du SAG

Bylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les patients atteints de CIFP et du SAG Ipsen met en avant...

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS Ipsen presents 3 late-breaking presentations and 8 abstracts across...

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today...

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus Ipsen presents 3 late-breaking presentations and 8 abstracts...

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	2.7	2.51162790698	107.5	110.8	107.4	32642	109.55297421	DE
4	1.2	1.10091743119	109	113.3	105.3	70591	109.19821822	DE
12	-3.8	-3.33333333333	114	117.5	105.3	61132	110.82725554	DE
26	-5.2	-4.50606585789	115.4	117.5	100.3	63440	109.48681872	DE
52	2	1.84842883549	108.2	126.7	99.7	70221	110.24188438	DE
156	29.58	36.690647482	80.62	130.7	77	79726	105.02028739	DE
260	31.3	39.670468948	78.9	130.7	34.2	100676	89.17114859	DE

IPN - Frequently Asked Questions (FAQ)

What is the current Ipsen share price?

The current share price of Ipsen is 110.20 €

How many Ipsen shares are in issue?

Ipsen has 82,029,421 shares in issue

What is the market cap of Ipsen?

The market capitalisation of Ipsen is EUR 9.07B

What is the 1 year trading range for Ipsen share price?

Ipsen has traded in the range of 99.70 € to 126.70 € during the past year

What is the PE ratio of Ipsen?

The price to earnings ratio of Ipsen is 14.03

What is the cash to sales ratio of Ipsen?

The cash to sales ratio of Ipsen is 2.68

What is the reporting currency for Ipsen?

Ipsen reports financial results in EUR

What is the latest annual turnover for Ipsen?

The latest annual turnover of Ipsen is EUR 3.37B

What is the latest annual profit for Ipsen?

The latest annual profit of Ipsen is EUR 644.4M

What is the registered address of Ipsen?

The registered address for Ipsen is 65 QUAI GEORGES GORSE, BOULOGNE-BILLANCOURT, HAUTS-DE-SEINE, 92100

What is the Ipsen website address?

The website address for Ipsen is www.ipsen.com

Which industry sector does Ipsen operate in?

Ipsen operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ALENREntreprendre	8.05 € (54.81%)	91
MLOCTOctopus Biosafety	0.182 € (45.60%)	42.07k
MLWEYWeya	0.0185 € (37.04%)	1,000
NACONNacon SA	0.76 € (26.25%)	918.49k
CANDCandela Invest	1.46 € (21.67%)	308
EIFDSTour Eiffel DS	0.012 € (-34.78%)	55.37k
MLFTIFrance Tourisme Immobilier	0.028 € (-21.13%)	3.44k
PROACProactis SA	0.0525 € (-20.45%)	5k
ALTROTronic s Microsystems	4.02 € (-19.60%)	28
ALNMRNamR SA	0.30 € (-14.29%)	22.63k
ATOAtos SE	0.0025 € (-7.41%)	2.59B
ALCYBCybergun	0.0001 € (0.00%)	46.82M
BCPBanco Comercial Portugues SA	0.465 € (1.04%)	46.42M
ALHPIHopium SA	0.0047 € (-6.00%)	18.2M
EDPEDP SA	3.099 € (-1.05%)	8.94M